突発難聴のアミドトリゾアート療法

概要

論文の詳細を見る
Clinical results of amidotrizoate therapy of sudden deafness during the last year were reported. Amidotrizoate used in thistherapy was 76% Urografin and it was injected intravenously 1--2m1 daily. Clinical data and audiograms of 17 cases which showed complete of almost complete recovery were showed in the tables and figures. The interval between onset of deafness and beginning of therapy was on an average 7days, the longest 43 days and the shortest 3days. The period during which hearing recovered was on an average for 7 days, most frequent by for 5 days. Three cases with bilateral hearing loss recovered bilaterally, but the pre-existing hearing loss showed no recovery. Clinical data of 15 cases showing no recovery were also reported and discussed. It was noed that the unrecovered cases were those with vertigo, those in which the beginning of theray was lated over 3 weeks and those in which some presumable causes of deafness had been found. In order to comfirm whether or not the new therapy was really effective the rate of recovery of hearing loss was compared with that of Simmons report and that of our own cases of recoverd completely by another therapy. It was concluded that the amidotrizoate was a specific medicament for the treatment of sudden deafness. From the results obtained, it was prsumed that sudden deafness should be a "barrier break deafness", "endolympb deafness" or "stria vasularis
社団法人日本耳鼻咽喉科学会の論文